Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer
Clinical Cancer Research, ISSN: 1078-0432, Vol: 15, Issue: 8, Page: 2630-2636
2009
- 227Citations
- 139Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations227
- Citation Indexes218
- 218
- CrossRef169
- Patent Family Citations5
- Patent Families5
- Clinical Citations2
- PubMed Guidelines2
- Policy Citations2
- Policy Citation2
- Captures139
- Readers139
- 139
- Mentions1
- Blog Mentions1
- Blog1
Article Description
Purpose: Tumors from 50% of epidermal growth factor receptor (EGFR) mutant non - small cell lung cancer patients that develop resistance to gefitinib or erlotinib will contain a secondary EGFR T790M mutation. As most patients do not undergo repeated tumor biopsies we evaluated whether EGFR T790M could be detected using plasma DNA. Experimental Design: DNA from plasma of 54 patients with known clinical response to gefitinib or erlotinib was extracted and used to detect both EGFR-activating and EGFR T790M mutations. Forty-three (80%) of patients had tumor EGFR sequencing (EGFR mutant/wild type: 30/13) and seven patients also had EGFR T790M gefitinib/erlotinib-resistant tumors. EGFR mutations were detected using two methods, the Scorpion Amplification Refractory Mutation System and theWAVE/Surveyor, combined with whole genome amplification. Results: Both EGFR-activating and EGFR T790M were identified in 70% of patients with known tumor EGFR-activating (21 of 30) orT790M (5 of 7) mutations. EGFR T790M was identified from plasma DNA in 54% (15 of 28) of patients with prior clinical response to gefitinib/erlotinib, 29% (4 of 14) with prior stable disease, and in 0% (0 of 12) that had primary progressive disease or were untreated with gefitinib/erlotinib. Conclusions: EGFR T790M can be detected using plasma DNA from gefitinib- or erlotinib- resistant patients. This noninvasive method may aid in monitoring drug resistance and in directing the course of subsequent therapy. © 2009 American Association for Cancer Research.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=65249127504&origin=inward; http://dx.doi.org/10.1158/1078-0432.ccr-08-2592; http://www.ncbi.nlm.nih.gov/pubmed/19351754; http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-08-2592; https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-08-2592; https://aacrjournals.org/clincancerres/article/15/8/2630/74776/Noninvasive-Detection-of-EGFR-T790M-in-Gefitinib; https://dx.doi.org/10.1158/1078-0432.ccr-08-2592; https://clincancerres.aacrjournals.org/content/15/8/2630
American Association for Cancer Research (AACR)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know